OneMedPlace announced today that Peter Neupert of Health Evolution Partners and Jack Young of Qualcomm Ventures will participate in programming for the 6th Annual OneMedForum, January 7-9, 2013, in San Francisco. The two experts will take part in a panel dedicated to ‘Digital and Connected Health,’ an emerging sector with significant and diverse investment opportunities.
Last week, OneMedRadio spoke with Immune Pharmaceuticals founder and CEO Dr. Daniel Teper and Epicept Corporation President and CEO Robert Cook, to discuss the merger and the clinical focus of the merged company going forward.
The 6th Annual OneMedForum will take place concurrently with the JP Morgan Healthcare Conference and will feature over 1,000 attendees and more than 100 emerging growth companies from the biotech and medical device sectors. The conference draws a diverse investor attendee base, including: venture capital, private equity, angel networks, family offices, hedge funds, high-net-worth individuals, international investors, research analysts, and strategic partners.
Fallout from the the US Supreme Court landmark decision to deny two patents to Prometheus Laboratories may complicate the future profitability of the industry. If this is indeed a precedent-setting decision, biomarker patents may now fall under the realm of “law of nature”, cutting off the prospect of exclusive market penetration that once justified the significant research and development onus in the early stages.
In Part II of our discussion with DARA Biosciences (NASDAQ: DARA) CEO and Chief Medical Officer Dr. David Drutz, we look into key catalysts for the specialty pharmaceutical company. Dr. Drutz discusses the medical need for the oral-liquid tamoxifen, Soltamox, licensed to DARA by UK-based Rosemont Pharmaceuticals — as well as the market opportunity in developing oncology services.
This is Part II of our special report on the state of immunotherapy in the public markets. This report looks at promising anticancer immunotherapy technologies, and the major issues in bringing these technologies to the general public.
Hosted by BioNJ, Pennsylvania Bio and Delaware Bio, their three word mission: “Find. Fund. Facilitate.” was clearly accomplished. Networking is still an integral part of these cerebral gatherings, however programming at this conference provided attendees with candid information, stimulating conversation and a new perspective on the industry.
NeoChord Inc., a venture-backed medical device company focused on minimally-invasive mitral valve repair, yesterday announced that its mitral valve repair system will be featured in the scientific program at the upcoming 26th Annual Meeting of the European Association for Cardio-Thoracic Surgery (EACTS).
CEVEC Pharmaceuticals GmbH (CEVEC), the developer of a novel human expression system for the manufacturing of complex biopharmaceuticals and vaccines announced today that it raised an additional amount of € 2.8 million in a Series C financing led by Peppermint VenturePartners (PVP) via the new Charité Biomedical Fund.
Intellicell BioSciences (OTC: SVFC) has pioneered a unique method of acquiring stromal vascular fraction cells derived from the blood vessels in the adult adipose tissue. The company’s proprietary protocol can separate adult autologous VFC cells from the adipose tissue without the use of enzymes.
Copyright © 2025 | WordPress Theme by MH Themes